Brief: FDA Grants Breakthrough Device Designation To Castle Biosciences’ Decisiondx-Melanoma Test
23/07/2025 12:23
July 23 (Reuters) - Castle Biosciences Inc CSTL.O: FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO CASTLE BIOSCIENCES’ DECISIONDX®-MELANOMA TEST Source text: ID:nGNX4xzQbn Further company coverage: CSTL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million